Parkinson’s Foundation (February 27, 2023) – Finding out you have Parkinson’s can be a lengthy process. Explore how a Parkinson’s diagnosis is made and what type of diagnostic tools are used.
Parkinson’s disease (PD)
A neurodegenerative disorder that affects predominately the dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.
Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:
Tremor, mainly at rest and described as pill rolling tremor in hands; other forms of tremor are possible
Slowness and paucity of movement (called bradykinesia and hypokinesia)
Limb stiffness (rigidity)
Gait and balance problems (postural instability)
In addition to movement-related (“motor”) symptoms, Parkinson’s symptoms may be unrelated to movement (“non-motor”). People with PD are often more impacted by their non-motor symptoms than motor symptoms. Examples of non-motor symptoms include: depression, anxiety, apathy, hallucinations, constipation, orthostatic hypotension, sleep disorders, loss of sense of smell, and a variety of cognitive impairments.
Cleveland Clinic – The American College of Cardiology’s Cardiovascular Disease in Women Committee released guidance on hormone therapy, with a focus on caring for women with a risk of heart disease. Leslie Cho, MD, explains what women should know about hormone therapy, and options available for women with heart disease risk factors.
Harvard Medical School – A 13-year international study in mice demonstrates that loss of epigenetic information, which influences how DNA is organized and regulated, can drive aging independently of changes to the genetic code itself.
It also shows that restoring the integrity of the epigenome reverses age-related symptoms.
“Diverse aging populations, vulnerable to chronic disease, are at the cusp of a promising future. Indeed, growing regenerative options offer opportunities to boost innate healing, and address aging-associated decline. The outlook for an extended well-being strives to achieve health for all,”
Regenerative medicine could slow the clock on degenerative diseases that often ravage the golden years, a Mayo Clinic study finds. Life span has nearly doubled since the 1950s, but health span — the number of disease-free years — has not kept pace. According to a paper published in NPJ Regenerative Medicine., people are generally living longer, but the last decade of life is often racked with chronic, age-related diseases that diminish quality of life. These final years come with a great cost burden to society.
Researchers contend that new solutions for increasing health span lie at the intersection of regenerative medicine research, anti-senescent investigation, clinical care and societal supports. A regenerative approach offers hope of extending the longevity of good health, so a person’s final years can be lived to the fullest.
As humans live longer, they’re at increased risk of developing devastating NEURODEGENERATIVE diseases, such as Alzheimer’s—in a treatment landscape with few options and little hope. At Scripps Research, scientists are closer than ever to understanding how these diseases harm the brain and identifying possible drugs to stop them.
“This early preclinical work may identify proteins that protect against cognitive loss. We know it’s a long path to get to a drug, but we’re creating the foundation. We know there’s an entire landscape of potential molecular interactions that maintain healthy synapses, and any of these proteins could be a drug target.”— Hollis Cline, PhD
Biomarkers are measurable indicators of what’s happening in your body. They can be found in blood, other body fluids, organs, and tissues, and can be used to track healthy processes, disease progression, or even responses to a medication. Biomarkers are an important part of dementia research.
For many older adults, a good night’s rest is elusive. The implications of chronically poor sleep can be far-reaching and include a decline in cognitive functioning and detrimental effects on health and general well-being. Fortunately, relief may be in sight.
A new study led by investigators at the Stanford University School of Medicine shows that neurons in the lateral hypothalamus, a brain region, play a pivotal role in sleep loss in old mice. More specifically, the arousal-promoting hypocretin neurons become hyperexcitable, driving sleep interruptions.
Luis de Lecea, PhD, is a professor of psychiatry and behavioral sciences at Stanford Medicine. He is the study’s senior author and hopes the finding could pave the way to new drug treatments for age-related sleep problems in humans.
Shi-Bin Li, PhD, is an instructor in the Psychiatry and Behavioral Sciences department at Stanford Medicine. He is also a basic life research scientist in the de Lecea lab, and is the lead author of the study. Lisa Kim is Senior Manager of Media Relations for Stanford Medicine and Stanford Health Care. Lisa has a deep background in journalism, as she is an Emmy Award-winning journalist who has covered stories on both the national and local levels.
Multimorbidity (two or more coexisting conditions in an individual) is a growing global challenge with substantial effects on individuals, carers and society. Multimorbidity occurs a decade earlier in socioeconomically deprived communities and is associated with premature death, poorer function and quality of life and increased health-care utilization. Mechanisms underlying the development of multimorbidity are complex, interrelated and multilevel, but are related to ageing and underlying biological mechanisms and broader determinants of health such as socioeconomic deprivation. Little is known about prevention of multimorbidity, but focusing on psychosocial and behavioural factors, particularly population level interventions and structural changes, is likely to be beneficial. Most clinical practice guidelines and health-care training and delivery focus on single diseases, leading to care that is sometimes inadequate and potentially harmful. Multimorbidity requires person-centred care, prioritizing what matters most to the individual and the individual’s carers, ensuring care that is effectively coordinated and minimally disruptive, and aligns with the patient’s values. Interventions are likely to be complex and multifaceted. Although an increasing number of studies have examined multimorbidity interventions, there is still limited evidence to support any approach. Greater investment in multimorbidity research and training along with reconfiguration of health care supporting the management of multimorbidity is urgently needed.